Adults with axial spondyloarthritis (axSpA) remained on golimumab longer than any other TNF inhibitor, according to a real-world analysis of medical records. Although adalimumab (marketed as Humira and biosimilars) was the most commonly prescribed first- and second-line TNF inhibitor, patients stayed with golimumab (marketed…
The levels of circulating cell-free DNA may be a biomarker for assessing disease activity and treatment response in people with ankylosing spondylitis (AS). The study, “Circulating cell-free DNA correlate to disease activity and treatment response of patients with radiographic axial spondyloarthritis”…
Poor sleep quality is highly prevalent among people with axial spondyloarthritis (axSpA) who have moderate to high disease activity and who don’t practice regular physical exercise, a study from Scandinavia reports. More physical activity and greater cardiorespiratory fitness were associated with better sleep. “The extent and magnitude of reduced sleep…
The decision to escalate treatment for people with highly active axial spondyloarthritis (axSpA) is mainly driven by the physician’s perspective on disease activity, a real-world study has revealed. Further research is needed to better understand these decisions and to optimize axSpA management, according to researchers in the study “…
Two or more comorbidities affected nearly half of the ankylosing spondylitis (AS) patients in a large study of the disease, with the most common coexisting conditions being uveitis (eye inflammation), depression, and hypertension (high blood pressure). Those with no comorbidities were younger and had shorter disease duration, the researchers reported,…
People with ankylosing spondylitis (AS) who report more severe pain and disease activity, and poorer quality of life, continue to work despite their AS — yet their productivity is far less than that of patients whose outcomes are not as severe. That’s according to a new analysis of data…
AVT05, Alvotech’s biosimilar candidate to treat ankylosing spondylitis (AS) and other chronic inflammatory diseases, showed a similar pharmacological profile to the reference medication Simponi (golimumab) in a clinical trial. The Phase 1 trial (NCT05632211) compared the safety, tolerability, and pharmacokinetics — movement into, through, and out…
Uveitis, a form of eye inflammation, and lower socioeconomic status are both linked to a longer time to diagnosis in people with axial spondyloarthritis, known as axSpA, a study reports. In contrast, older age at symptom onset is associated with shorter delays, the researchers noted. “These results suggest that…
A man with ankylosing spondylitis (AS) went into disease remission within three months of receiving BCD-180, an experimental antibody designed to deplete a type of immune cell called TRBV9-positive T-cells, a study reports. He also stopped treatment with the TNF inhibitors he had taken continuously for five years,…
Up to five years of treatment with bimekizumab safely leads to sustained reductions in symptoms and disease activity, as well as improvements in physical function and life quality, for people with ankylosing spondylitis (AS). That’s according to new data from the now-completed Phase 2b BE AGILE clinical…
Get regular updates to your inbox.